A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Sotio Biotech Inc.
SystImmune Inc.
Myeloid Therapeutics
SEED Therapeutics, Inc.
NextCure, Inc.
Black Diamond Therapeutics, Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Silverback Therapeutics
Mannkind Corporation